Aurobindo gets USFDA nod for dexamethasone sodium phosphate injection

摘要

Hyderabad-based Aurobindo Pharma Ltd. has received final approval from the USFDA to manufacture and market dexamethasone sodium phosphate injection. The approved ANDA is bioequi-valent and therapeutically equivalent to the reference drug product of Luit- pold Pharmaceuticals Inc. The injection is used in the treatment of various conditions such as severe allergic reactions, arthritis, blood diseases, breathing problems, certain cancers, eye diseases, intestinal disorders and skin diseases.